Allergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman
October 26 2016 - 8:20PM
Dow Jones News
Allergan PLC named Chief Executive Brent Saunders to the
additional post of chairman, succeeding Paul Bisaro.
Mr. Bisaro was chief executive from 2007 through 2014, and has
since served as executive chairman. He will remain on the
board.
Mr. Bisaro steered the company once known as Watson
Pharmaceuticals Inc. through a significant period of growth.
Watson bought Forest Laboratories, whose CEO was Mr. Saunders,
and Actavis Group, and then took the Actavis name. In 2015, Actavis
PLC bought Allergan Inc. for about $70.5 billion and changed its
name to Allergan PLC.
Allergan said Wednesday that board member Christopher Coughlin
was elected lead independent director. Mr. Coughlin is chairman of
Dun & Bradstreet Corp.
This year, Allergan sold its generics business to Teva
Pharmaceutical Industries Ltd. for $40.5 billion and struck deals
to buy companies including Tobira Therapeutics Inc. and Vitae
Pharmaceuticals Inc.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 26, 2016 20:05 ET (00:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
